Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 4/20 | 0.35 |
| ▸ | RORC | P51449 | 9/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | TGM1 | P22735 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450192 | 0.88 | RORC (0.35) | STSRORCNR1H2HTR6PDK4 | |
| SCHEMBL19176058 | 0.88 | RORC (0.35) | STSRORCNR1H2HTR6PDK4 | |
| SCHEMBL2256948 | 0.86 | NR1H2 (0.40) | STSRORCF13A1TGM2TGM1 | |
| SCHEMBL23538445 | 0.84 | RORC (0.37) | STSRORCF13A1TGM2TGM1 | |
| SCHEMBL19168628 | 0.82 | RORC (0.38) | STSRORCF13A1TGM2TGM1 | |
| SCHEMBL25322322 | 0.82 | NR1H2 (0.35) | STSRORCF13A1TGM2TGM1 | |
| SCHEMBL5809590 | 0.81 | RORC (0.37) | STSRORCF13A1TGM2TGM1 | |
| SCHEMBL27147183 | 0.80 | GRM1 (0.38) | RORCGRM5GRM1NR1H2PDK4 | |
| SCHEMBL16434814 | 0.79 | RORC (0.33) | STSRORCF13A1TGM2TGM1 | |
| SCHEMBL21111698 | 0.78 | RORC (0.34) | STSRORCNR1H2HTR6PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2832728-B1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL IND LTD (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2832728-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | STS 3075/4885RORC 897/4885F13A1 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.